PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal(University of the Witwatersrand), Evan A. Stein(Louisville Metabolic and Atherosclerosis Research Center), Robert Dufour(Université de Montréal), Traci Turner(Louisville Metabolic and Atherosclerosis Research Center), Fernando Civeira(Hospital Universitario Miguel Servet), Lesley Burgess(Tygerberg Hospital), Gisle Langslet(Oslo University Hospital), Russell Scott(University of Otago), Anders Olsson(Linköping University), David Sullivan(Royal Prince Alfred Hospital), G. Kees Hovingh(Academic Medical Center), Bertrand Cariou(Institut du Thorax), Ioanna Gouni‐Berthold(University of Cologne), Ransi Somaratne(Amgen (United States)), Ian Bridges(Amgen (United Kingdom)), Robert C. Scott(Amgen (United States)), Scott M. Wasserman(Amgen (United States)), Daniel Gaudet(Université de Montréal)
Cited by 746
Abstract
Related Papers
No related papers found
Powered by citation graph analysis